Resonant Clinical Solutions Expands European Services Via Acquisition

Resonant Clinical Solutions has expanded its specialized services in Europe through the acquisition of Creapharm Bioservices. This move enhances the company's offerings for supporting advanced therapies, particularly in cell and gene therapy, and bolsters its cryogenic storage capabilities.

The acquisition significantly boosts Resonant's global biobanking services within Europe. This strengthens the company's capacity to support complex and demanding clinical programs on the continent. The new capabilities enable enhanced support for cell and gene therapy programs, which are rapidly growing sectors in medicine.

Resonant Clinical Solutions CEO Jane Doe stated that the acquisition is a strategic step for the company's growth in the European market. She emphasized that the purchase considerably improves Resonant's ability to provide comprehensive solutions to its clients in these fast-evolving therapeutic fields.

The company anticipates that the combined resources and expertise will further solidify its position as a provider of clinical services. Furthermore, the transaction is expected to accelerate the development and market introduction of new promising treatments.